|
3-5-1 Nihombashi-honcho, Chuo-ku Tokyo 103-8426, Japan Tel. +81-3-6255-1111 Fax +81-3-6255-1132 |
Type: Public
On the web:
http://www.daiichisankyo.co.jp
Daiichi Sankyo is the product of a spurt of merger mania in the Japanese drug business. After Sankyo purchased rival Daiichi Pharmaceutical for more than $7 billion in 2005, the two companies merged their operations into the newly formed Daiichi Sankyo, creating a top pharmaceutical manufacturer in Japan. Daiichi Sankyo manufactures prescription drugs, including treatments for cardiovascular, bone and joint, and infectious diseases. Its products are sold through medical representatives located worldwide. The company also makes over-the-counter (OTC) and generic drugs, as well as veterinary products and assorted chemicals.
Key numbers for fiscal year ending March, 2008:
Sales: $8,863.7M
One year growth: 12.4%
Net income: $983.5M
Income growth: 47.6%
Officers:
Chairman and Representative Director: Kiyoshi Morita
President, CEO, and Representative Director: Takashi Shoda
Executive officer and General Manager, International Business Management Department: George Nakayama
Competitors:
Astellas
Shionogi & Co.
Takeda Pharmaceutical
